Erik J Bonten
Overview
Explore the profile of Erik J Bonten including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
621
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zudeh G, Franca R, Lucafo M, Bonten E, Bramuzzo M, Sgarra R, et al.
Life Sci Alliance
. 2023 Jan;
6(3).
PMID: 36596605
PACSIN2 variants are associated with gastrointestinal effects of thiopurines and thiopurine methyltransferase activity through an uncharacterized mechanism that is postulated to involve autophagy. This study aims to clarify the role...
2.
Ferguson D, McCorkle J, Barnett K, Bonten E, Bergeron B, Bhattarai K, et al.
Blood Adv
. 2022 Jun;
6(11):3386-3397.
PMID: 35671062
Understanding the genomic and epigenetic mechanisms of drug resistance in pediatric acute lymphoblastic leukemia (ALL) is critical for further improvements in treatment outcomes. The role of transcriptomic response in conferring...
3.
Zou C, Beard J, Yang G, Evans W, Bonten E
J Inflamm Res
. 2022 Feb;
15:1183-1194.
PMID: 35221708
Background: Following our 2015 elucidation of the CASP1/NALP3 inflammasome mechanism of glucocorticoid (GC)-resistance in pediatric acute lymphoblastic leukemia (ALL) patients, we engineered a cell-based CASP1/NALP3 reporter system suitable for high-throughput...
4.
Diouf B, Wing C, Panetta J, Eddins D, Lin W, Yang W, et al.
Clin Transl Sci
. 2021 Mar;
14(4):1490-1504.
PMID: 33742760
Vincristine (VCR) is one of the most widely prescribed medications for treating solid tumors and acute lymphoblastic leukemia (ALL) in children and adults. However, its major dose-limiting toxicity is peripheral...
5.
Lucafo M, Granata S, Bonten E, McCorkle R, Stocco G, Caletti C, et al.
Clin Transl Sci
. 2020 Dec;
14(3):964-975.
PMID: 33382913
To assess whether NLRP3 gene promoter methylation was able to discriminate glucocorticoid (GC)-resistant from GC-sensitive idiopathic nephrotic syndrome (INS), patients with minimal change disease (MCD) or focal segmental glomerulosclerosis (FSGS),...
6.
Lopez-Lopez E, Autry R, Smith C, Yang W, Paugh S, Panetta J, et al.
J Clin Invest
. 2020 Nov;
130(12):6600-6615.
PMID: 33164984
BACKGROUNDInterpatient differences in the accumulation of methotrexate's active polyglutamylated metabolites (MTXPGs) in leukemia cells influence its antileukemic effects.METHODSTo identify genomic and epigenomic and patient variables determining the intracellular accumulation of...
7.
Autry R, Paugh S, Carter R, Shi L, Liu J, Ferguson D, et al.
Nat Cancer
. 2020 Sep;
1(3):329-344.
PMID: 32885175
Identification of genomic and epigenomic determinants of drug resistance provides important insights for improving cancer treatment. Using agnostic genome-wide interrogation of mRNA and miRNA expression, DNA methylation, SNPs, CNAs and...
8.
Paugh S, Bonten E, Evans W
Mol Cell Oncol
. 2016 Jun;
3(1):e1065947.
PMID: 27308575
In primary acute lymphoblastic leukemia cells exhibiting de novo resistance to glucocorticoids, we recently discovered decreased promoter methylation of caspase 1 (CASP1) and NLR family, pyrin domain containing 3 (NLRP3),...
9.
Paugh S, Coss D, Bao J, Laudermilk L, Grace C, Ferreira A, et al.
PLoS Comput Biol
. 2016 Feb;
12(2):e1004744.
PMID: 26844769
MicroRNAs are important regulators of gene expression, acting primarily by binding to sequence-specific locations on already transcribed messenger RNAs (mRNA) and typically down-regulating their stability or translation. Recent studies indicate...
10.
Paugh S, Bonten E, Savic D, Ramsey L, Thierfelder W, Gurung P, et al.
Nat Genet
. 2015 May;
47(6):607-14.
PMID: 25938942
Glucocorticoids are universally used in the treatment of acute lymphoblastic leukemia (ALL), and resistance to glucocorticoids in leukemia cells confers poor prognosis. To elucidate mechanisms of glucocorticoid resistance, we determined...